77 related articles for article (PubMed ID: 12393636)
1. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P; Perkins EB; Honeycut C; Wellons MD; Stefan T; Jacobberger JW; Kontopodis E; Beumer JH; Egorin MJ; Imamura CK; Douglas Figg W; Karp JE; Koc ON; Cooper BW; Luger SM; Colevas AD; Roberts JD; Grant S
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1657-67. PubMed ID: 22349810
[TBL] [Abstract][Full Text] [Related]
3. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
Rink L; Slupianek A; Stoklosa T; Nieborowska-Skorska M; Urbanska K; Seferynska I; Reiss K; Skorski T
Blood; 2007 Jul; 110(2):651-60. PubMed ID: 17431132
[TBL] [Abstract][Full Text] [Related]
4. A method for screening and validation of resistant mutations against kinase inhibitors.
Kesarwani M; Huber E; Kincaid Z; Azam M
J Vis Exp; 2014 Dec; (94):. PubMed ID: 25549138
[TBL] [Abstract][Full Text] [Related]
5. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
Lin YL; Roux B
J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor Trapping in Kinases.
Spassov DS; Atanasova M; Doytchinova I
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542228
[TBL] [Abstract][Full Text] [Related]
7. Structural mechanism of a drug-binding process involving a large conformational change of the protein target.
Ayaz P; Lyczek A; Paung Y; Mingione VR; Iacob RE; de Waal PW; Engen JR; Seeliger MA; Shan Y; Shaw DE
Nat Commun; 2023 Apr; 14(1):1885. PubMed ID: 37019905
[TBL] [Abstract][Full Text] [Related]
8. Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.
Hayes KE; Walk EL; Ammer AG; Kelley LC; Martin KH; Weed SA
Oncogene; 2013 Oct; 32(40):4766-77. PubMed ID: 23146907
[TBL] [Abstract][Full Text] [Related]
9. Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism.
Wilson C; Agafonov RV; Hoemberger M; Kutter S; Zorba A; Halpin J; Buosi V; Otten R; Waterman D; Theobald DL; Kern D
Science; 2015 Feb; 347(6224):882-6. PubMed ID: 25700521
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells.
Pham TM; Ahmed M; Lai TH; Bahar ME; Hwang JS; Maulidi RF; Ngo QN; Kim DR
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474202
[TBL] [Abstract][Full Text] [Related]
11. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
Lin YL; Meng Y; Huang L; Roux B
J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
[TBL] [Abstract][Full Text] [Related]
12. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase.
Hoemberger M; Pitsawong W; Kern D
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19221-19227. PubMed ID: 32719139
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics and protein function.
Karplus M; Kuriyan J
Proc Natl Acad Sci U S A; 2005 May; 102(19):6679-85. PubMed ID: 15870208
[TBL] [Abstract][Full Text] [Related]
14. Structure, regulation, signaling, and targeting of abl kinases in cancer.
Hantschel O
Genes Cancer; 2012 May; 3(5-6):436-46. PubMed ID: 23226581
[TBL] [Abstract][Full Text] [Related]
15. (Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia.
Pimentel LCF; Hoelz LVB; Canzian HF; Branco FSC; de Oliveira AP; Campos VR; Júnior FPS; Dantas RF; Resende JALC; Cunha AC; Boechat N; Bastos MM
Beilstein J Org Chem; 2021; 17():2260-2269. PubMed ID: 34621389
[TBL] [Abstract][Full Text] [Related]
16. Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.
Breitkopf SB; Yuan M; Helenius KP; Lyssiotis CA; Asara JM
Anal Chem; 2015 Nov; 87(21):10995-1006. PubMed ID: 26434776
[TBL] [Abstract][Full Text] [Related]
17. Label-free detection of small-molecule-protein interactions by using nanowire nanosensors.
Wang WU; Chen C; Lin KH; Fang Y; Lieber CM
Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3208-12. PubMed ID: 15716362
[TBL] [Abstract][Full Text] [Related]
18. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
19. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bernt KM; Hunger SP
Front Oncol; 2014; 4():54. PubMed ID: 24724051
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
